| Literature DB >> 35745270 |
Magdalena Jodkiewicz1, Agnieszka Jagiełło-Gruszfeld2, Agnieszka Surwiłło-Snarska1, Beata Kotowicz3, Małgorzata Fuksiewicz3, Maria Małgorzata Kowalska3.
Abstract
Background: Obesity is an independent prognostic factor and is associated with poorer response to oncological treatment of breast cancer. Obesity is associated with shorter overall survival and shorter time to recurrence. Material and methods: The study included 104 breast cancer patients qualified for neoadjuvant chemotherapy. The control group consisted of 40 patients who refused to participate in the study. Consultation before chemotherapy included: author's diet questionnaire, body composition analysis, nutrition education. After chemotherapy, the effects of the first dietary advice were evaluated.Entities:
Keywords: body fat; breast cancer; diet; neoadjuvant chemotherapy; obesity
Mesh:
Substances:
Year: 2022 PMID: 35745270 PMCID: PMC9228308 DOI: 10.3390/nu14122541
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 6.706
Characteristics of the study and control group.
| Variable | Parameter | Dietary Consultation Group | Control Group | ||
|---|---|---|---|---|---|
| N = 104 | % | N = 40 | % | ||
|
| 0 | 1 | 1 | 0 | 0 |
| 1 | 8 | 7.7 | 4 | 10 | |
| 2 | 58 | 55.7 | 23 | 57.5 | |
| 3 | 34 | 32.7 | 12 | 30 | |
| 4d | 3 | 2.9 | 1 | 2.5 | |
|
| 0 | 49 | 47.2 | 10 | 25 |
| 1 | 46 | 44.2 | 25 | 62.5 | |
| 2 | 5 | 4.8 | 4 | 10 | |
| 3 | 4 | 3.8 | 1 | 2.5 | |
|
| 1 | 11 | 10.5 | 3 | 7.5 |
| 2 | 65 | 62.5 | 29 | 72.5 | |
| 3 | 28 | 27 | 8 | 20 | |
|
| positive | 40 | 38.5 | 12 | 30 |
| negative | 64 | 61.5 | 28 | 70 | |
|
| positive | 32 | 30.8 | 11 | 27.5 |
| negative | 72 | 69.2 | 29 | 72.5 | |
|
| positive | 15 | 14,4 | 4 | 10 |
| negative | 89 | 85.6 | 36 | 90 | |
|
| TCarbH | 15 | 14.4 | 4 | 10 |
| ACdd/ | 45 | 43.3 | 19 | 47.5 | |
| AC/PCL weekly | 44 | 42.3 | 17 | 42.5 | |
|
| pCR | 64 | 61.5 | 22 | 55 |
| Non-pCR | 40 | 38.5 | 18 | 45 | |
cT—clinical tumour; cN—clinical nodes; G—grade; ER—oestrogen receptor; PR—progesterone receptor; HER2—human epidermal growth factor receptor 2; TCaH—docetaxel, carboplatin, trastuzumab; ACdd/PCL—doxorubicin, cyclophosphamide dose dense (every 2 weeks), paclitaxel; AC/PCL—doxorubicin, cyclophosphamide (every 3 weeks), paclitaxel; pCR—pathological complete response; non-pCR—non pathological complete response.
Figure 1Flow chart—schematic of the study. * All participants in the study survived and completed chemotherapy, and the proportion of patients who did not return after treatment was due to reasons beyond the study design. We suspect that in some participants, the reasons were ill health and distance of residence from the treatment centre.
Distribution of BMI and percentage body fat in the study group of patients.
| All | Before Menopause | After the Menopause | |
|---|---|---|---|
| BMI: <18.49 | 3 (2.9%) | 3 (4.2%) | 0 (0%) |
| BMI: 18.5–24.99 | 43 (41.4%) | 36 (50%) | 7 (21.9%) |
| BMI: 25.0–29.99 | 33 (31.7%) | 17 (23.6) | 16 (50%) |
| BMI: ≥30 | 25 (24%) | 16 (22.2%) | 9 (28.1%) |
| %Fat—normal | 54 (51.9%) | 41 (57%) | 13 (40.6%) |
| %Fat above normal | 43 (41.4%) | 25 (34.7%) | 18 (56.3%) |
| % Fat below normal | 7 (6.7%) | 6 (8.3%) | 1 (3.1%) |
Mean concentrations of body composition analysis parameters according to hormonal status.
| All | Before Menopause | After the Menopause | |||||
|---|---|---|---|---|---|---|---|
| Average | SD | Average | SD | Average | SD | ||
|
| 31.6 | 7.4 | 29.8 | 7.1 | 35.2 | 7.0 |
|
| Fat mass (kg) | 22.2 | 8.3 | 20.6 | 7.9 | 25.3 | 8.3 |
|
| FFM—Fat-free Mass (kg) | 45.4 | 5.9 | 45.6 | 6.4 | 45.0 | 5.0 | 0.540 |
| TBW—Total body water (%) | 33.5 | 3.6 | 33.8 | 3.6 | 32.9 | 3.7 | 0.458 |
SD—standard deviation *—p < 0.05.
Mean levels of lipid metabolism parameters before treatment by hormonal status.
| All | Before Menopause | After the Menopause | |||||
|---|---|---|---|---|---|---|---|
| Average | SD | Average | SD | Average | SD | ||
|
| 188.2+ | 46.5 | 178.5 | 45.9 | 207.7 | 41.9 |
|
| HDL (mg/dL) | 53.9 | 14.4 | 52.3 | 15.8 | 57.0 | 10.9 | 0.05 |
| LDL (mg/dL) | 113.1 | 33.7 | 110.2 | 31.0 | 119.5 | 39.2 | 0.54 |
| TG (mg/dL) | 107.7 | 60.8 | 99.7 | 52.9 | 124.1 | 72.9 | 0.138 |
SD—standard deviation *—p < 0.05.
Changes in the results of anthropometric parameters of body composition analysis before and after chemotherapy.
| N = 75 | Before | After | Change | ||||
|---|---|---|---|---|---|---|---|
| Average | SD | Average | SD | Average | SD | ||
|
| 68.2 | 12.0 | 68.4 | 11.5 | 0.1 | 4.4 | 0.671 |
| BMI (kg/m2) | 25.3 | 4.4 | 25.5 | 4.3 | 0.1 | 1.4 | 0.274 |
| Fat (%) | 31.6 | 7.4 | 30.2 | 6.8 | −1.8 | 3.9 |
|
| Fat mass (kg) | 22.2 | 8.3 | 21.4 | 7.8 | −1.2 | 3.5 |
|
| FFM—fat-free mass (kg) | 45.4 | 5.9 | 47.1 | 5.9 | 1.5 | 5.4 |
|
| TBW—total body water (%) | 33.5 | 3.6 | 34.8 | 3.5 | 1.2 | 1.4 |
|
SD—standard deviation *—p < 0.05.
Changes in concentration of laboratory parameters before and after chemotherapy.
| N = 75 | Before | After | Change | ||||
|---|---|---|---|---|---|---|---|
| Average | SD | Average | SD | Average | SD | ||
|
| 188.2 | 46.4 | 196.6 | 44.4 | 8.9 | 48.4 |
|
| HDL (mg/dL) | 53.9 | 14.4 | 50.7 | 11.0 | −3.3 | 10.4 |
|
| LDL (mg/dL) | 113.1 | 33.7 | 124.4 | 54.3 | 12.6 | 52.5 |
|
| TG (mg/dL) | 107.7 | 60.8 | 146.8 | 84.9 | 42.1 | 74.6 |
|
SD—standard deviation *—p < 0.05.
Dietary assessment based on scores from the author’s questionnaire before education and treatment and after treatment.
| N = 75 | Before | After | Change | ||||
|---|---|---|---|---|---|---|---|
| Average | SD | Average | SD | Average | SD | ||
|
| 7.4 | 3.5 | 12.2 | 3.3 | 4.8 | 4.4 |
|
SD—standard deviation *—p < 0.05.
Changes in body weight and BMI values before and after chemotherapy in the control and study groups.
| Control Group | Study Group | ||||
|---|---|---|---|---|---|
| Average | SD | Average | SD | ||
|
| 1.8 | 3.8 | 0.1 | 4.4 |
|
| Delta BMI (kg/m2) | 0.7 | 1.4 | 0.1 | 1.4 | 0.05 |
SD—standard deviation *—p < 0.05.